Outcomes Study: Implementation of the Vectra® Test into Health-System Specialty Pharmacy Practice

Members of our team had the opportunity to present a new poster abstract at NASP inSPIRE 2026, which was held from September 22-25, 2026.

CPS Authors

Casey Fitzpatrick, PharmD; Amber Skrtic, PharmD; Muhamed Miljkovic, PharmD; Sara Kissinger, PharmD; Anne Falen, PharmD

Background

• CPS-managed health-system specialty pharmacies (HSSPs) play a critical role in supporting the monitoring of disease activity in patients with rheumatoid arthritis (RA), often leveraging patient-reported outcome measures (PROMs) such as the Routine Assessment of Patient Index Data 3 (RAPID3).

• The Vectra test integrates concentrations of 12 serum biomarkers with select patient characteristics (i.e., age, sex, and adiposity) to generate a composite score that reflects RA disease activity and predicts risk of radiographic progression,¹ providing an objective complement to PROMs and traditional clinical assessment.

• HSSPs are well positioned to operationalize the Vectra test into existing clinical workflows as a complement to RAPID3.²

Objectives

To describe the integration of the Vectra test into routine RA clinical management within a HSSP.